Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)
Stopped The study did not meet the pilot feasibility endpoints and was formally closed to accrual prematurely on February 8, 2017.
Conditions
Interventions
- DRUG: Dose dense AC-P
- DRUG: Dose dense AC
- DRUG: FEC-D
Sponsor
Ottawa Hospital Research Institute